AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02122081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
Study NCT03013764 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: normal protein diet
Description: subjects will undergo 10 days of low physical activity while consuming a normal protein diet
Study NCT03013764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high protein intake
Description: subjects will undergo 10 days of low physical activity while consuming a high protein diet
Study NCT04291456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline 100mg
Description: Single-arm trial of minocycline 100 mg twice daily
Study NCT02887222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml
Study NCT00053352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03191214 — intervention group
Intervention type: DEVICE
Intervention: Intraoperative Forced Air Warming
Description: As part of their standard care, patients undergoing surgery >30 min in duration will receive forced air warming in the form of a Bair Hugger. This is a blanket covering their upper torso and arms into which warm air is blown.
Study NCT04181437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1203-R1
Description: 1 tablet, Single oral dosing
Study NCT04181437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1203-R2
Description: 1 tablet, Single oral dosing
Study NCT04181437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1203-R1 and NVP-1203-R2
Description: NVP-1203-R1,1 tablet and NVP-1203-R2, 1 tablet, co-administration, single oral dosing
Study NCT03024528 — intervention group
Intervention type: BEHAVIORAL
Intervention: CPOT assessment
Description: Polish version of Critical care pain observation tool validation.
Study NCT04385875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine + extension of the ATI period
Description: During the AELIX-002 trial participants received the following: DNA.HTI at weeks 0, 4, and 8 and MVA.HTI at weeks 12 and 20 (DDDMM) followed by ChAdOx1.HTI at weeks 0 and 12 and MVA.HTI at week 24 (CCM), starting at least 24 weeks after MVA.HTI week 20. After that, on ATI_extension trial, ATI will be extended for 48 weeks.
Study NCT04385875 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + extension of the ATI period
Description: During the AELIX-002 trial participants received the following: Normal saline solution at weeks 0, 4, 8, 12, and 20 (PPPPP) followed by normal saline solution at weeks 0, 12 and 24 (PPP), starting at least 24 weeks after week 20 administration. After that, on ATI_extension trial, ATI will be extended for 48 weeks.
Study NCT01428687 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Duration
Description: Subjects are taught sleep hygiene strategies to increase their sleep; they record their sleep in a diary and wear an actigraph and call in their sleep to the office each day.
Study NCT01428687 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No change in sleep
Description: This group is taught to maintain their current sleep habits.
Study NCT00932451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: PF-02341066, 250 mg BID, will be administered orally on a continuous schedule
Study NCT01712893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex
Description: Eligible patients were randomly divided into 2 groups, the intervention group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,and the control group should use chemotherapy alone followed by Zoladex
Study NCT01712893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex
Description: Eligible patients were randomly divided into 2 groups, the intervention group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,and the control group should use chemotherapy alone followed by Zoladex
Study NCT03652948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meru Health Ascend Program
Description: Cognitive-behavioral skills, mindfulness
Study NCT04007107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (administered by DV3396 pen)
Description: Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
Study NCT04007107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (administered by PDS290 pen)
Description: Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
Study NCT02122081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
Study NCT02122081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00284297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: History taken and clinical examination
Description: History is taken and clinical examination is followed
Study NCT01298856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hydrotherapy
Description: hydrotherapy and ankle taping and land-based
Study NCT04022499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Presessions
Description: The Pre-NDPP arm includes a pre-session with three components: 1) education about diabetes risks, 2) motivational interviewing (MI) to encourage participation in the NDPP and, 3) problem-solving of barriers to engagement.
Study NCT04022499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: National Diabetes Prevention Program
Description: The Diabetes Prevention Program was a successful clinical trial demonstrating that intensive lifestyle support for weight loss reduced diabetes incidence by 58%. The intervention was translated into the National Diabetes Prevention Program (NDPP) and disseminated by the Centers for Disease Control and Prevention as a yearlong group-based program since 2012.
Study NCT04022499 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: National Diabetes Prevention Program
Description: The Diabetes Prevention Program was a successful clinical trial demonstrating that intensive lifestyle support for weight loss reduced diabetes incidence by 58%. The intervention was translated into the National Diabetes Prevention Program (NDPP) and disseminated by the Centers for Disease Control and Prevention as a yearlong group-based program since 2012.
Study NCT04143113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Shared decision making tool
Study NCT02380846 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: White rice
Description: Control - white rice
Study NCT02380846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice with chicken breast
Description: Treatment 1 - steamed white rice with steamed chicken breast
Study NCT02380846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice with fish
Description: Treatment 2 - steamed white rice with steamed fish
Study NCT02380846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice with egg white
Description: Treatment 3 - steamed white rice with egg white
Study NCT02380846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice with beancurd
Description: Treatment 4 - steamed white rice with steamed beancurd
Study NCT04060823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Easy Breathing program
Description: Easy Breathing is a longstanding, nationally recognized program that translates asthma management guidelines into a standardized and usable format for healthcare providers. As part of the program primary healthcare providers will identify children at-risk for adverse asthma outcomes and provide care coordination services. Patients receive a tailored, comprehensive Asthma Treatment Plan with information regarding daily medication use and management of acute symptoms based on asthma severity.
Study NCT03395821 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training
Description: traditional training according to residency program
Study NCT03395821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality+conventional training
Description: virtual reality training+traditional training using virtual reality
Study NCT01974895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluLaval® Quadrivalent
Description: 1 or 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
Study NCT01974895 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone®
Description: 1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
Study NCT00662129 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00662129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00662129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Study NCT04601584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 1, GNR-084
Description: 0.01 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
Study NCT04601584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 2, GNR-084
Description: 0.1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
Study NCT04601584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 3, GNR-084
Description: 1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
Study NCT03477994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 ,if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.
Study NCT03477994 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Clonidine
Description: an infusion of 0.5μg/kg then 0.1-0.2 μg/kg/h if Richmond assessment sedation score from +1 to +4.
Study NCT04477044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group
Description: GoPro Hero4 to be mounted on the participant's forehead while performing intubation on a manikin.
Study NCT03768024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT0151Y 50 mg capsule
Description: GRT0151Y 50 mg capsule
Study NCT03768024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone IR 4 mg
Description: Hydromorphone IR 4 mg tablet (encapsulated)
Study NCT03768024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo
Study NCT00553852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant GH Saizen (Merck-Serono)
Description: Treatment will start at the initial dose 0.15-0.30 mg/day; dose adjustment will be performed according to IGF-I levels. The duration of medical treatment is 6 months.
Study NCT00553852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant GH Saizen (Merck-Serono)
Description: Treatment will start at the initial dose 0.15-0.30 mg/day; dose adjustment will be performed according to IGF-I levels. The duration of medical treatment is 6 months.
Study NCT01479192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide
Description: 100mg (2cps/day) for 5 years
Study NCT01479192 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 cpr/day of matched placebo for 5 years
Study NCT02594774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulative osteopathy
Description: Osteopathic treatment (BMT) which works on the influence on the pressure distribution in the (especially abdominal) body cavities and consequently on the viscera contained therein, proper arterial supply and venous and limphatic drainage.
Study NCT04363918 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: bioelectric stimulation
Description: bioelectric stimulation
Study NCT04363918 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bioelectric stimulation
Description: bioelectric stimulation
Study NCT03364517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Predictor score of the imminence of a childbirth (SPIA)
Description: The SPIA score is based on the analysis of 6 types of criteria: panic during the call, the possibility of having a telephone contact with the parturient, the urge to push and if so for how long, the rhythm of the CU, some aggravating factors (history of fast delivery or at home, maternal age between 26 and 35 years, lack of follow-up of pregnancy) and 2 minor factors (nulliparity and the taking of a tocolytic treatment). Each criteria is between 0 to 8, except for the 2 minor criteria for which 7 and 3 points are removed if they are present. This gives a score between -10 and +33, which is weighted according to the admission time estimated at the hospital (30 minutes, 1h and 2h).
Study NCT02086448 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevents apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
Study NCT02086448 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-CPAP
Study NCT02086448 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sleep hygiene
Description: Information about sleep apnea and healthy sleep. Information about local sleep resources
Study NCT01461252 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryoablation
Description: For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
Study NCT01461252 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiation
Description: Radiation therapy is usually performed with 6-18 Megavolt photons from a linear accelerator. The proposed dose and frequency of radiation for this protocol are: 8 Gray in 1 fraction, 30 Gray in 10 fractions, or 37.5 Gray in 15 fractions. These proposed doses or other doses will be prescribed at the discretion of the investigator. It is anticipated that subjects will begin the radiation therapy approximately within one to three weeks after the cryoablation procedure. The doses and frequency of the radiation treatment will be collected as well as toxicities.
Study NCT03347344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: 50 mg will be administered (per os) twice a day
Study NCT03347344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg will be administered (per os) twice a day
Study NCT03356899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose bupivacaine 0.5% (8mg)
Description: 8 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.1 ml
Study NCT03356899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose bupivacaine 0.5% (10mg)
Description: 10 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.5
Study NCT02295761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling (Fb)
Description: Facebook-delivered lifestyle counseling
Study NCT02295761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling + activity monitor (Fb+Act)
Description: Facebook-delivered lifestyle counseling and self-monitoring physical activity using Polar activity monitor
Study NCT01720329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Active comparator Arm. XXmls of XXX supplemented with XX of L. rhamnosus GG on a daily basis for six months
Study NCT01720329 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: probiotic placebo
Description: Placebo comparator arm -Participants randomized to placebo will receive XXmls of XXX G on a daily basis for 6 months.
Study NCT03133091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PIEB: Patient Intermittent Epidural Boluses
Description: Each patient were randomized to PIEB (7 ml bolus every 30 minutes, with extra boluses (PCEA) of 6 ml every 20 minutes) or PCEA (5 ml in continuous perfussion + PCEA of 5 ml every 15 minutes).
Study NCT03133091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCEA: Patient Controlled Epidural Analgesia
Description: Each patient were randomized to PIEB (7 ml bolus every 30 minutes, with extra boluses (PCEA) of 6 ml every 20 minutes) or PCEA (5 ml in continuous perfussion + PCEA of 5 ml every 15 minutes).
Study NCT04191941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel CAR-T
Description: A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of Novel CAR-T cells
Study NCT04543721 — intervention group
Intervention type: DEVICE
Intervention: 24-h-ABPM
Description: 24-h- blood pressure measurement and pulse wave analysis
Study NCT02046772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine low dose
Description: A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
Study NCT02046772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine standard dose
Description: Single intradural standard dose of bupivacaine
Study NCT02046772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Chloride
Description: A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
Study NCT02268370 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib
Study NCT04505605 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: A blood sample will be collected on a dry tube with 5mL separating gel on each enrolled patients. Those will be made depending on the patients hospitalization.
Study NCT01279564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETview TVT endotracheal tube
Description: intubation
Study NCT01279564 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Endotracheal tube
Description: Intubation
Study NCT02655419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATM-AVI
Description: Cohort 1:~(Creatinine clearance > 50 mL/min)6500mg ATM/1777mg AVI on day 1 followed by total daily dose of 6000mg ATM/1640mg AVI~Cohorts 2 and 3:~(Creatinine clearance > 50 mL/min) As above, or: 6500 mg ATM/2167 mg on Day 1 followed by a total daily dose of 6000 mg ATM/2000 m AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1162 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/820 mg AVI, or:~4250 mg ATM/1417 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/1000 mg AVI
Study NCT02655419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 500mg infused over 1 hour every 8 hours
Study NCT00046917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00046917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00046917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT02425761 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventriculoperitoneal shunt insertion surgery
Description: The most common treatment for hydrocephalus is the placement of a ventriculoperitoneal shunt in the operating room. A shunt is a flexible tube placed into the ventricular system, fluid filled chambers, of the brain that diverts the flow of CSF into another region of the body, usually the abdomen, also known as the peritoneal cavity, where it can be absorbed.
Study NCT03407183 — intervention group
Intervention type: PROCEDURE
Intervention: intradetrusor injection of botulinumtoxinA (Botox)
Description: intradetrusor injection of botulinumtoxinA (Botox®, Allergan, Irvine, USA) to assess the efficacy of Botox in treatment of neurogenic bladder.
Study NCT02335749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The CoolSculpting System with a Small Area Applicator will be used to deliver treatments.
Study NCT04102865 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Negative-Pressure Wound Therapy (NPWT)
Description: Investigational single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 7 days.